Figure 1.

Antitumor activity of low−dose apatinib monotherapy as the third−line treatment in patients with metastatic colorectal cancer. (A) Best percentage changed from the baseline in measurable tumor lesions shown by a waterfall plot. (B) Kaplan−Meier survival curve of the PFS of the patients from low−dose apatinib treatment. (C) Kaplan−Meier survival curve of OS of the patients from the low−dose apatinib treatment. (D) PFS and (E) OS in patients who were previously treated with or without bevacizumab. mCRC = metastatic colorectal cancer, OS = overall survival, and PFS = progression−free survival.